WO2008107677A3 - Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders - Google Patents

Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders Download PDF

Info

Publication number
WO2008107677A3
WO2008107677A3 PCT/GB2008/000761 GB2008000761W WO2008107677A3 WO 2008107677 A3 WO2008107677 A3 WO 2008107677A3 GB 2008000761 W GB2008000761 W GB 2008000761W WO 2008107677 A3 WO2008107677 A3 WO 2008107677A3
Authority
WO
WIPO (PCT)
Prior art keywords
nr9r10
treatment
alkoxy
hydroxyl
halogen
Prior art date
Application number
PCT/GB2008/000761
Other languages
French (fr)
Other versions
WO2008107677A2 (en
Inventor
David Ian Carter Scopes
Timothy John Cheeseright
Jeremy Gilbert Vinter
Original Assignee
Senexis Ltd
David Ian Carter Scopes
Timothy John Cheeseright
Jeremy Gilbert Vinter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senexis Ltd, David Ian Carter Scopes, Timothy John Cheeseright, Jeremy Gilbert Vinter filed Critical Senexis Ltd
Publication of WO2008107677A2 publication Critical patent/WO2008107677A2/en
Publication of WO2008107677A3 publication Critical patent/WO2008107677A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X is an oxygen or sulphur atom A is CH(R6)-, -O- or NR7 or when A is NR7, then R1 and NR7 can together form a ring such that R1 and R7 are (CH2)n, where n is 2-4, preferably 2-3; Y is a bond, CH(R6)-, -O- or NR7 or A and Y together form a single bond between the aromatic group and the carbonyl group but when A is-O- then Y is not -O-; R1 and R2 are independently hydrogen, halogen, OR8, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by fluorine, hydroxyl, C1-6 alkoxy or NR9R10; R3 is C1-6 alkyl, C3-8 cycloalkyl C4-10 alkylcycloalkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R4 is hydrogen, halogen, CF3, OR9, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R5 is hydrogen, halogen, CF3, OR8, COOR9, CONR9R10 or SO2R11; The compounds find use in the treatment of amyloid related diseases, such as Alzheimer disease.
PCT/GB2008/000761 2007-03-07 2008-03-06 Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders WO2008107677A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0704394.6A GB0704394D0 (en) 2007-03-07 2007-03-07 Compounds
GB0704394.6 2007-03-07

Publications (2)

Publication Number Publication Date
WO2008107677A2 WO2008107677A2 (en) 2008-09-12
WO2008107677A3 true WO2008107677A3 (en) 2008-10-30

Family

ID=37966087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000761 WO2008107677A2 (en) 2007-03-07 2008-03-06 Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders

Country Status (2)

Country Link
GB (1) GB0704394D0 (en)
WO (1) WO2008107677A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2177521A1 (en) * 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
EP2305660A1 (en) * 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) * 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
JP5944823B2 (en) * 2010-07-02 2016-07-05 あすか製薬株式会社 Heterocyclic compound and p27Kip1 degradation inhibitor
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
CN105636953B (en) 2013-07-31 2018-01-02 诺华股份有限公司 1,4 dibasic pyridyl derivatives and its purposes for treating the illness related to SMN shortages
US10538516B2 (en) 2015-03-25 2020-01-21 National Center For Geriatrics And Gerontology Oxadiazole derivative and pharmaceutical containing same
CN105384736B (en) * 2015-10-28 2018-11-02 南昌大学 A kind of type Ⅳ collagen enzyme inhibitor and synthetic method
CN108794427B (en) * 2018-07-13 2022-07-29 江苏快达农化股份有限公司 Synthetic method of 1,3, 4-thiadiazole derivative

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020991A1 (en) * 2003-08-21 2005-03-10 Pfizer Products, Inc. Compounds for the treatment of neurodegenerative disorders
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
WO2005095368A1 (en) * 2004-04-01 2005-10-13 Pfizer Products Inc. Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
WO2007125351A1 (en) * 2006-04-27 2007-11-08 Senexis Limited Pyrimidine derivatives for the treatment of amyloid-related diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020991A1 (en) * 2003-08-21 2005-03-10 Pfizer Products, Inc. Compounds for the treatment of neurodegenerative disorders
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
WO2005095368A1 (en) * 2004-04-01 2005-10-13 Pfizer Products Inc. Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
WO2007125351A1 (en) * 2006-04-27 2007-11-08 Senexis Limited Pyrimidine derivatives for the treatment of amyloid-related diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
GB0704394D0 (en) 2007-04-11
WO2008107677A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2008107677A3 (en) Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders
RS20080242A (en) Bicyclic cinnamide compound
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
EA200700572A1 (en) COMPOUND 2-MORFOLIN-4-PYRIMIDON
MX2007006896A (en) Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer s disease.
NO20084302L (en) 2- (cyclic amino) pyrimidone derivatives as TPK1 inhibitors
WO2008038051A3 (en) Use of ion channel modulators in the prophylaxis and treatment of inflammatory and immunological diseases
NO20045528L (en) MHC1R antagonists
WO2005087771A3 (en) 5,6-dialkyl-7-amino-triazolopyrimidines, method for their production, their use for controlling pathogenic fungi and agents containing said compounds
HK1165954A1 (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
MX2009008781A (en) Spirocyclic cyclohexane derivatives.
WO2007057790A3 (en) Substituted bicyclic pyrimidone derivatives
NO20091858L (en) Hydrobenzamide derivatives as inhibitors of HSP90
MX360667B (en) Ethynyl derivatives as mglur5 allosteric modulators.
ZA200805758B (en) Triazolone derivative
TNSN07014A1 (en) New heterocyclic carboxylic acid amide derivatives
MX2009004884A (en) Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[ 1,2-a]pyrimidin-6-one derivatives.
WO2008136378A1 (en) Novel sulfonamide derivative and salt thereof
IL201795A0 (en) Stereoisomers propofol therapeutic compounds
TW200700429A (en) Process for production of glucopyranosyloxypyrazole derivative
AR079509A1 (en) BICYCLE TIAZOLS AS MGLUR5 ALLOSTERIC RECEIVER MODULATORS
WO2009016812A1 (en) Prophylactic and/or therapeutic agent for anemia comprising 2-phenylquinoline-4-carboxylic acid derivative as active ingredient
HK1143591A1 (en) Inhibitor of binding of s1p1
UA91572C2 (en) Bicyclic cinnamide compound
TW200501938A (en) A medicament for therapeutic treating overactive urinary bladder accompany with cerebrovascular disorder

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08718622

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08718622

Country of ref document: EP

Kind code of ref document: A2